Meeder Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.02M | Buy |
16,853
+8,950
| +113% | +$522K | 0.06% | 165 |
|
|
2025
Q4 | $426K | Buy |
7,903
+7,440
| +1,607% | +$358K | 0.02% | 219 |
|
|
2025
Q3 | $20.9K | Buy |
463
+21
| +5% | +$981 | ﹤0.01% | 423 |
|
|
2025
Q2 | $20.5K | Buy |
442
+78
| +21% | +$3.83K | ﹤0.01% | 515 |
|
|
2025
Q1 | $22.2K | Sell |
364
-177
| -33% | -$10.3K | ﹤0.01% | 523 |
|
|
2024
Q4 | $30.6K | Sell |
541
-31,131
| -98% | -$1.74M | ﹤0.01% | 453 |
|
|
2024
Q3 | $1.64M | Buy |
31,672
+15,329
| +94% | +$719K | 0.11% | 114 |
|
|
2024
Q2 | $679K | Sell |
16,343
-113,460
| -87% | -$5.08M | 0.05% | 142 |
|
|
2024
Q1 | $7.04M | Buy |
129,803
+64,433
| +99% | +$3.28M | 0.44% | 56 |
|
|
2023
Q4 | $3.35M | Buy |
65,370
+60,122
| +1,146% | +$3.16M | 0.26% | 92 |
|
|
2023
Q3 | $305K | Sell |
5,248
-58,369
| -92% | -$3.58M | 0.02% | 216 |
|
|
2023
Q2 | $4.07M | Buy |
63,617
+378
| +0.6% | +$25.3K | 0.3% | 77 |
|
|
2023
Q1 | $4.38M | Buy |
63,239
+10,243
| +19% | +$722K | 0.35% | 70 |
|
|
2022
Q4 | $3.81M | Sell |
52,996
-64,245
| -55% | -$4.84M | 0.33% | 77 |
|
|
2022
Q3 | $8.34M | Sell |
117,241
-19,900
| -15% | -$1.44M | 0.48% | 43 |
|
|
2022
Q2 | $10.6M | Buy |
137,141
+7,363
| +6% | +$561K | 0.61% | 34 |
|
|
2022
Q1 | $9.48M | Buy |
129,778
+109,969
| +555% | +$7.38M | 0.46% | 49 |
|
|
2021
Q4 | $1.24M | Sell |
19,809
-160,000
| -89% | -$9.39M | 0.12% | 128 |
|
|
2021
Q3 | $10.6M | Buy |
179,809
+1,315
| +0.7% | +$86.6K | 0.56% | 37 |
|
|
2021
Q2 | $11.9M | Buy |
178,494
+33,015
| +23% | +$2.15M | 0.56% | 36 |
|
|
2021
Q1 | $9.18M | Buy |
145,479
+129,320
| +800% | +$8.05M | 0.47% | 44 |
|
|
2020
Q4 | $1M | Sell |
16,159
-127,335
| -89% | -$7.83M | 0.22% | 84 |
|
|
2020
Q3 | $8.65M | Buy |
143,494
+4,392
| +3% | +$264K | 0.56% | 39 |
|
|
2020
Q2 | $8.18M | Buy |
139,102
+7,903
| +6% | +$473K | 0.53% | 45 |
|
|
2020
Q1 | $7.31M | Buy |
131,199
+3,578
| +3% | +$219K | 0.57% | 39 |
|
|
2019
Q4 | $8.19M | Buy |
127,621
+115,165
| +925% | +$6.6M | 0.5% | 59 |
|
|
2019
Q3 | $631K | Sell |
12,456
-40,837
| -77% | -$1.92M | 0.04% | 359 |
|
|
2019
Q2 | $2.42M | Sell |
53,293
-18,618
| -26% | -$867K | 0.17% | 118 |
|
|
2019
Q1 | $3.43M | Buy |
71,911
+816
| +1% | +$40.6K | 0.27% | 93 |
|
|
2018
Q4 | $3.7M | Buy |
71,095
+25,449
| +56% | +$1.37M | 0.33% | 76 |
|
|
2018
Q3 | $2.83M | Buy |
45,646
+19,346
| +74% | +$1.15M | 0.21% | 114 |
|
|
2018
Q2 | $1.46M | Sell |
26,300
-52,902
| -67% | -$2.86M | 0.13% | 156 |
|
|
2018
Q1 | $5.01M | Buy |
79,202
+19,699
| +33% | +$1.27M | 0.46% | 55 |
|
|
2017
Q4 | $3.65M | Buy |
59,503
+49,550
| +498% | +$3.1M | 0.31% | 83 |
|
|
2017
Q3 | $635K | Buy |
9,953
+6,221
| +167% | +$363K | 0.07% | 324 |
|
|
2017
Q2 | $208K | Buy |
+3,732
| New | +$203K | 0.02% | 467 |
|
|
2016
Q4 | – | Sell |
-36,331
| Closed | -$1.96M | – | 984 |
|
|
2016
Q3 | $1.96M | Sell |
36,331
-14,762
| -29% | -$948K | 0.17% | 134 |
|
|
2016
Q2 | $3.76M | Buy |
51,093
+5,322
| +12% | +$376K | 0.35% | 51 |
|
|
2016
Q1 | $2.92M | Buy |
45,771
+36,102
| +373% | +$2.28M | 0.27% | 78 |
|
|
2015
Q4 | $665K | Sell |
9,669
-6,077
| -39% | -$402K | 0.06% | 258 |
|
|
2015
Q3 | $931K | Buy |
+15,746
| New | +$999K | 0.09% | 211 |
|
|
2014
Q3 | – | Sell |
-275
| Closed | -$13K | – | 377 |
|
|
2014
Q2 | $13K | Sell |
275
-9,779
| -97% | -$482K | ﹤0.01% | 313 |
|
|
2014
Q1 | $522K | Buy |
10,054
+515
| +5% | +$27.4K | 0.09% | 174 |
|
|
2013
Q4 | $507K | Sell |
9,539
-670
| -7% | -$34.1K | 0.09% | 181 |
|
|
2013
Q3 | $472K | Buy |
10,209
+410
| +4% | +$18K | 0.09% | 164 |
|
|
2013
Q2 | $438K | Buy |
+9,799
| New | +$425K | 0.09% | 165 |
|
Other funds holding BMY
VCM
VPM
Meeder Asset Management's BMY Position: Q1 2026 in Review
Meeder Asset Management increased its Bristol-Myers Squibb (BMY) stake by 113% in Q1 2026, buying an estimated $522K and bringing the position to 16,853 shares worth $1.02M. The position accounts for 0.06% of the portfolio, ranked #165.
Meeder Asset Management first reported a position in BMY in Q2 2013 and has held it in 46 quarters since. The position peaked at $11.9M in Q2 2021. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Meeder Asset Management held 16,853 shares of Bristol-Myers Squibb worth $1.02M as of Q1 2026.
- Meeder Asset Management bought 8,950 Bristol-Myers Squibb shares in Q1 2026, an estimated $522K.
- Bristol-Myers Squibb made up 0.06% of Meeder Asset Management's portfolio in Q1 2026, its #165 holding.
- Meeder Asset Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 46 quarters since.
- Meeder Asset Management's Bristol-Myers Squibb position peaked at $11.9M in Q2 2021.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.